Dr. Chris Airriess, CEO of CorTechs Labs, a leading breakthrough medical device software solutions company that offers cutting edge brain imaging analysis, discusses the changing landscape of neuroimaging and the software/data analytics created to optimize it and aid efficient, more accurate diagnoses especially with Alzheimer’s and MS.
Dr. Chris Airriess, CEO of CorTechs Labs. Dr. Airriess has a long history of connecting business and science in the development of med-tech solutions. As CEO of CorTechs Labs, he drives the strategic development of the company, which has pioneered the application of volumetric MRI in routine clinical practice. Over the past 12 years, CorTechs Labs’ flagship MRI product, NeuroQuant, has been the go-to application for fast, objective volumetric analysis of neurodegenerative conditions such as Alzheimer’s, multiple sclerosis, epilepsy, and traumatic brain injury. Previously, as Chief Operating Officer of California Stem Cell (acquired by Caladrius Biosciences), Dr. Airriess drove company development from startup to the clinical development phase of several therapeutic candidates, including FDA approval through Phase III clinical trial using autologous stem cells to treat metastatic melanoma. Other positions held include Assistant Professor at the University of British Columbia, Canada, and Director of Scientific Computing for the National Center for Microscopy and Imaging Research and the Biomedical Informatics Research Network, both headquartered at the University of California, San Diego. Dr. Airriess has a Ph.D. in cardiovascular physiology and was a postdoctoral fellow at the University of Cambridge, UK and the University of Sydney, Australia.